Spots Global Cancer Trial Database for stage iii bladder urothelial carcinoma ajcc v6 and v7
Every month we try and update this database with for stage iii bladder urothelial carcinoma ajcc v6 and v7 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer | NCT03419130 | Infiltrating Bl... Stage II Bladde... Stage III Bladd... | Hypofractionate... Laboratory Biom... Pembrolizumab Radiation Thera... | 18 Years - | University of California, San Francisco | |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study | NCT05987241 | Muscle Invasive... Stage II Bladde... Stage III Bladd... Stage IV Bladde... | Biospecimen Col... cfDNA or ctDNA ... Computed Tomogr... Magnetic Resona... Nivolumab Quality-of-Life... Questionnaire A... Relatlimab | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery | NCT02178241 | Metastatic Uret... Metastatic Uret... Stage III Bladd... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe... | Eribulin Mesyla... Gemcitabine Hyd... | 18 Years - | National Cancer Institute (NCI) | |
| Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations | NCT03047213 | Locally Advance... Metastatic Tran... Metastatic Urot... Recurrent Bladd... Stage III Bladd... Stage IV Bladde... | Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery | NCT02812420 | Hydronephrosis Infiltrating Bl... Infiltrating Bl... Infiltrating Bl... Infiltrating Re... Renal Pelvis Ur... Stage II Bladde... Stage II Renal ... Stage II Ureter... Stage II Urethr... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe... | Durvalumab Therapeutic Con... Tremelimumab | 18 Years - | M.D. Anderson Cancer Center | |
| Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer | NCT03419130 | Infiltrating Bl... Stage II Bladde... Stage III Bladd... | Hypofractionate... Laboratory Biom... Pembrolizumab Radiation Thera... | 18 Years - | University of California, San Francisco | |
| Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction | NCT00365157 | Advanced Urothe... Locally Advance... Metastatic Urot... Recurrent Uroth... Stage III Bladd... Stage IV Bladde... Unresectable Ur... | Eribulin Mesyla... Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery | NCT02178241 | Metastatic Uret... Metastatic Uret... Stage III Bladd... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe... | Eribulin Mesyla... Gemcitabine Hyd... | 18 Years - | National Cancer Institute (NCI) | |
| Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations | NCT03047213 | Locally Advance... Metastatic Tran... Metastatic Urot... Recurrent Bladd... Stage III Bladd... Stage IV Bladde... | Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo | NCT03421652 | Stage II Bladde... Stage III Bladd... Stage IV Bladde... | Nivolumab Radiation | 18 Years - | Barbara Ann Karmanos Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
